Free Trial

Getinge (OTCMKTS:GNGBY) Short Interest Up 133.3% in August

Getinge logo with Medical background

Key Points

  • Getinge's short interest surged by 133.3% in August, escalating from 300 shares to a total of 700 shares as of August 31st.
  • The company received a hold rating from Sanford C. Bernstein, while its overall consensus rating remains a hold among analysts.
  • Currently, Getinge's stock trades at $22.66, showing a decrease of 0.7% during midday trading, and has a market capitalization of $6.17 billion.
  • Interested in Getinge? Here are five stocks we like better.

Getinge (OTCMKTS:GNGBY - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 700 shares, an increase of 133.3% from the August 15th total of 300 shares. Based on an average trading volume of 4,200 shares, the days-to-cover ratio is currently 0.2 days. Based on an average trading volume of 4,200 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Separately, Sanford C. Bernstein upgraded shares of Getinge to a "hold" rating in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Getinge has a consensus rating of "Hold".

View Our Latest Research Report on GNGBY

Getinge Trading Down 0.7%

Shares of GNGBY traded down $0.17 during midday trading on Friday, hitting $22.66. The stock had a trading volume of 1,037 shares, compared to its average volume of 1,816. Getinge has a 1 year low of $14.84 and a 1 year high of $22.85. The firm has a market cap of $6.17 billion, a PE ratio of 42.75 and a beta of 1.08. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.22 and a quick ratio of 0.70. The stock's 50 day moving average is $20.88 and its 200 day moving average is $20.27.

Getinge (OTCMKTS:GNGBY - Get Free Report) last announced its earnings results on Friday, July 18th. The company reported $0.23 earnings per share for the quarter. Getinge had a net margin of 4.24% and a return on equity of 10.46%. The business had revenue of $852.59 million for the quarter.

Getinge Company Profile

(Get Free Report)

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Getinge Right Now?

Before you consider Getinge, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Getinge wasn't on the list.

While Getinge currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.